ArticleCurrent drug metabolism2026
Chiglitazar Demonstrates Potential to Treat Metabolic Dysfunction-Associated Steatohepatitis
Article in Current drug metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionChiglitazar was approved by the China National Medical Products Administration (NMPA) in 2021 for the treatment of patients with type 2 diabetes mellitus, and may also benefit from metabolic dysfunction-associated steatohepatitis (MASH).
methodsTo characterise the role of Chiglitazar in MASH, in vitro experiments examining monocyte activation and migration were conducted, alongside liver and stellate cell proliferation assays. Three distinct MASH animal models (db/db mouse model, MCD model, CCl4 model) for conducting in vivo studies were established.
resultsThe results indicated that Chiglitazar reduced MCP-1-induced THP-1 migration and down-regulated TNF-α and MCP-1 expression. It also blocked TGF-β-driven proliferation in dermal fibroblasts and hepatic stellate cells while suppressing α-SMA and CTGF expression. In vivo, Chiglitazar alleviates hepatic steatosis and inflammation in the MCD model, whilst improving hepatic inflammation and fibrosis in both the CCL4 and HFD+CCL4 models. DISCUSSION: In the study, it has been demonstrated that chiglitazar suppresses monocyte activation and chemotaxis, thereby attenuating chronic inflammation-elicited vascular and tissue damage. It also blocks fibroblast proliferation and differentiation, curbing toxin- or metabolite- induced inflammation and fibrosis. Although CCl4, MCD, and HFD+CCl4 models were used, they only partially reproduce human MASH pathology. Future work should employ more physiologically faithful systems.
conclusionAs the world's first pan-PPAR agonist approved for the treatment of Type 2 Diabetes Mellitus (T2DM), Chiglitazar has also demonstrated potential for treating MASH by modulating steatosis, inflammation, and fibrosis. This potential may be translatable into clinical treatments in the foreseeable future.
Indexed as
Identifiers
42836505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.